Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
"Frankly, I am optimistic, even more so as we sit at 3.70. I personally think this is all manipulation and games along with being a Nasdaq Russell 2000 biotech stock.
My 2 short term positive indicators are:
1) checking daily morningstar's fund & institutional ownership % and the speed of accumulation to 20-25%
2) if and when the C's get fed again with options/RSU's
I truly would not be surprised if a 3rd party came forward before Dec 30.
When we thought Ocata would boom they crashed so why can't it be when we think they will bust they boom?
IMO Lupus, Sepsis, MS, and ultimately Alzheimers and Cancer via Lanza's science are the real golden nuggets that a buyer is after. The game is to see if it is possible to get it all IMO."
BF This post was by Bogeyfree.
Philosophy is not what i stand for myself. The ability of this company to help afflicted people is worth standing for. IMO
If the company did not have success written up in the Lancet Peer Reiewed Journal, then i'd think twice before taking this stand in the endeaver to rid people of this terrible condition and obtain wealth.
OCAT went up over 600% when phase 1 started they had success but only with rats and were allowed the approval to work on humans. Now with phase 2 about to start it will be very interesting to see what happens. Co-incidentily, the share price is in the same range as the last time share price rose big time. The company had hardly no money at that time.
Now the company has 32 million in the bank and major success written up in the Lancet Scientific Peer Reviewed Journal with spectacular results in macular degeneration. No one has helped this unmet medical need like OCAT. Other companies have only slowed the degresion. OCAT has stopped it in all patients and has brought improvement in 1/2 of the patients, some spectacular. Results like 20/40 from 20/400 are recorded.
Old OCAT un-updated information is not valid. Here is the recent information August 7th 2015
"And finally, we are significantly strengthened our balance sheet with a $30 million common stock offering, attracting institutional capital was the key goal for the first half of 2015, and I'm pleased that we completed this offering"
Some finacial companies show the old info from 4th quarter of last year. Not the true updated info.
OCAT has picked up even more followers recently. OCAT chart fluxuates, sometimes 3.80 is even for the day and sometimes it shows it below even. My Vanguard account shows 3.80 as even.
OCAT: "we have reported good progress in the clinic in multiple trials of macular degeneration in the past year. We've shown that we can reliably manufacture our RPE product. We have a healthy balance sheet. We have a robust intellectual property position. We have a good and developing pipeline behind the RPE program"
What is the highest price OCAT has ever been "without" the 32 Million they now have in the bank?
$OCAT @OcataThx CC Transcript-8/6/15: U.S. BREAKTHROUGH STATUS intent shortly "once a Pivotal SMD trial is initiated"
BANK OF NEW YORK MELLON CORP buying OCAT
http://www.nasdaq.com/symbol/ocat/institutional-holdings#ixzz3iCKkjPkW
When you fill in the OCAT chart to a 5 year chart and then update, it is certain that OCAT can turn on a dime.
http://stockcharts.com/h-sc/ui
California teachers retirement fund. Did someone say they loaded up on OCAT?
Do you have a link that proves your opinion?
Chart players care. EOM
OCAT has done some amazing things for the traders.
Makes since to me to invest in a company that has shown it can go up 600% from here quickly. IMO everyone has and should have their own point of view. If mine is not popular, so be it.
Just look at the 5 year OCAT chart if you think differently. If you can find one. Here is one. Fill in the chart for five years then update.
http://stockcharts.com/h-sc/ui
How many OCAT investors have macular degeneration? My interest are in the investors that want the company to succeed for the sake of the patients and for their investment. I agree it is childlike to control people with guilt. However, for the sake of the patients if the shoe fits wear it.
By all means you have a right to get your beer money. Use sarcasm if necessary. In the mean time OCAT patients need this company to succeed.
Preventing Depression in Macular Degeneration Patients
www.amdblog.org/ macular-degeneration Proxy Highlight
Dec 21, 2012 ... Depression with macular degeneration often stems from feelings of rage ... may be too preoccupied with thoughts of suicide or despair to sleep.
For me it does not matter if anyone hates the CEO, seems too emotional to me.
OCAT Dr. Wotton was named New Jersey 2014 EY Entrepreneur of the Year in Life Sciences.
Now if you said you hate the patients that have improved tremendously from OCAT science, like 20/40 from 20/400. Then i'd take it personally. By the way, the improvements of OCAT patients is verified in the Lancet Scientific Peer Reviewed Journal.
Someone is wrong, either it's Wotton or the ones that hate Wotton.
Maybe both?
Definitely there is a gap to fill at $6.20 When you look at the five year OCAT chart. Change to five years and than update, it shows a gap and run up 600%.
http://stockcharts.com/h-sc/ui
For me the company has made significant progress in many ways.
OCAT increased study sites while improved with five new dynamic patents.
Plus: "after phase 2 has begun yes they were anticipating the breakthrough application."
Hey OCAT: This baby's oversold. People thought that the company used over 3.75 million shares when in fact it came to only 1/2 million.
OCAT CEO, "said, they believe they have increased-the-value of this company from the past"
quote: "He basically said that there is no reason for such a decline. We are in a much better position than before. Nothing fundamental has changed."
OCAT "extended lead in race to market" when Japan's program went down with major setback. OCAT Dr. Robert Lanza said Japan should look OCAT's way for better answers and solutions.
OCAT had .50m share increase not 3million
OCAT Balance sheet improved.
If OCAT jumps up 600% like it did five years ago from this low price.
The start of phase1 went up big fast...if phase2 starts, the same thing could/might happen. I dont believe in crystal ball opinions, just facts and possibilities. Have you found a five year OCAT chart yet to prove big ups happen with OCAT?
Held strong also Lode, and still breathing as well.
Good eye etpa.
It's been mentioned before, maybe Japan's patients need help with OCATA technology. Here is some quotes from the web about the subject.
"Ocata Competitor's AMD ips stem cell trial halted due to cancer scare"
https://www.newscientist.com/article...ure-blindness/
"As I said on another thread Japan should immediately partner with Ocata and bring in the real experts!"
BF
"the good Dr. robert is getting marketing savvy...love his quote.."
“I think it’s an easily fixable problem if they go this route,” says Robert Lanza, chief scientist at Advanced Cell Technology/OCAT in Marlborough, Massachusetts, a company that is also developing stem-cell therapies for age-related blindness"
"This sounds horrible, but the failure of these trials will ultimately help Ocata a lot. One by one, the inferior and not-ready-for-prime time stem cell treatments are falling. And since this is the treatment I would need... well, I think I have the cred to say it!!"
"Well the cell source used in the Japanese trials used ips cell derived using viral vectors to alter the cell back to its embryonic like state and the ips cells Ocata is using uses mRNA to alter it which Lanza has always said was the safe way to derive these cells. Maybe your response was retorical and you knew this already but if there's anyone that didn't know the difference between Ocatas technique and Japan's, there it is."
Big institutions are buying OCAT according to morningstar.
The last time OCAT went up 600% OCAT had less going for it. Now,
OCAT quote: "The company has published unprecedented trial results, has strengthened its balance sheet, has continued to advance its portfolio of intellectual property, has secured management contracts from key scientists and has replaced former management with a new team that is experienced in the development of small biotech companies."
Is OCAT in the start of a 600%-climbup like 5 years ago? Does everyone have a five year chart of OCAT? Could OCAT go higher this time?
OCAT quote: "The company has published unprecedented trial results, has strengthened its balance sheet, has continued to advance its portfolio of intellectual property, has secured management contracts from key scientists and has replaced former management with a new team that is experienced in the development of small biotech companies."
AyeEye, it's easy to see the analogy in the video helping people to see. OCAT is doing a fantastic job along these lines.
Nothing like getting your eyesight back or seeing for the first time. Go OCAT !!! GLTA including patients.
Could the big inflection point for OCAT be with the data readout on that first cohort of dry AMD patients, which will be reporting?
If the Lancet Journal likes OCAT and phase1 soared shareprice. What will phase2 bring? When it happened in phase1 it happened quick. You can see on this chart. A good chart to save in favorites. Scroll down where is says fill in the chart to 5 year chart then go back up and hit update. You will see a huge rise in shareprice.
http://stockcharts.com/h-sc/ui
This OCAT chart shows details. The last time OCAT was this low it changed directions about five years ago. Chart players/ bottom feeders heads up.
http://stockcharts.com/h-sc/ui
OCAT succeeds in helping macular degeneration.
http://www.reuters.com/article/2015/03/31/ma-ocata-therapeutics-idUSnBw315282a+100+BSW20150331
LOL Dr. RobertLanza has done well for OCAT/Patients.
"First comes the bitterness, then there is sweetness and wealth for 10,000 years”
Good thinking AyeEye OCAT has several other ways ahead to add to success.
A few did not believe phase1 would happen, a few did not believe the Lancet Journal would confirm macular degeneration improvements in patients or for that matter, they did not believe results would even would even be published. A few do not believe phase2 will happen. OCAT comes through contrary to a few people.
I'm very happy with phase1 success. It is a first for mankind improving macular degeneration. The patients that can benefit in phase2 are worth the future improvments they'll get.